- Home
- SILC vs CNTX Comparison
SILC vs CNTX Comparison
Compare SILC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CNTX
- Stock Information
- Founded
- SILC 1987
- CNTX 2015
- Country
- SILC Israel
- CNTX United States
- Employees
- SILC N/A
- CNTX N/A
- Industry
- SILC Computer Manufacturing
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- CNTX Health Care
- Exchange
- SILC Nasdaq
- CNTX Nasdaq
- Market Cap
- SILC 99.6M
- CNTX 113.0M
- IPO Year
- SILC 1994
- CNTX 2021
- Fundamental
- Price
- SILC $18.59
- CNTX $1.15
- Analyst Decision
- SILC Hold
- CNTX Strong Buy
- Analyst Count
- SILC 1
- CNTX 7
- Target Price
- SILC N/A
- CNTX $5.20
- AVG Volume (30 Days)
- SILC 23.4K
- CNTX 564.2K
- Earning Date
- SILC 10-30-2025
- CNTX 11-06-2025
- Dividend Yield
- SILC N/A
- CNTX N/A
- EPS Growth
- SILC N/A
- CNTX N/A
- EPS
- SILC N/A
- CNTX N/A
- Revenue
- SILC $58,651,000.00
- CNTX N/A
- Revenue This Year
- SILC $6.53
- CNTX N/A
- Revenue Next Year
- SILC $14.10
- CNTX N/A
- P/E Ratio
- SILC N/A
- CNTX N/A
- Revenue Growth
- SILC N/A
- CNTX N/A
- 52 Week Low
- SILC $12.29
- CNTX $0.49
- 52 Week High
- SILC $19.37
- CNTX $2.38
- Technical
- Relative Strength Index (RSI)
- SILC 63.52
- CNTX 48.30
- Support Level
- SILC $16.75
- CNTX $1.19
- Resistance Level
- SILC $17.50
- CNTX $1.34
- Average True Range (ATR)
- SILC 0.64
- CNTX 0.13
- MACD
- SILC 0.07
- CNTX -0.03
- Stochastic Oscillator
- SILC 95.96
- CNTX 9.09
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.